

# Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/R61ADF79FA1EN.html>

Date: December 2019

Pages: 234

Price: US\$ 2,000.00 (Single User License)

ID: R61ADF79FA1EN

## Abstracts

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2019

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2019, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.

Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and

features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 15, 3, 1, 35 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 11 molecules, respectively.

Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Retinitis Pigmentosa (Retinitis) - Overview

Retinitis Pigmentosa (Retinitis) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development

4D Molecular Therapeutics Inc

Acucela Inc

Advanced Medical Projects

Allegro Ophthalmics LLC

Allergan Plc

Alpine Biotherapeutics Corp

Amarantus Bioscience Holdings Inc

Amgen Inc

Ankar Pharma SL

Applied Genetic Technologies Corp

Biogen Inc

Brighton Biotech Inc

Casebia Therapeutics

Dompe Farmaceutici SpA

Editas Medicine Inc

Endogena Therapeutics Inc

EyePoint Pharmaceuticals Inc

Eyestem Research Pvt Ltd

Eyevenys SAS

GenSight Biologics SA

Grupo Ferrer Internacional SA

Horama SA

ID Pharma Co Ltd  
IVERIC bio Inc  
jCyte Inc  
Kyoto Drug Discovery & Development Co Ltd  
Lineage Cell Therapeutics Inc  
MeiraGTx Holdings Plc  
MimeTech Srl  
Miragen Therapeutics Inc  
Mireca Medicines GmbH  
NanoScope Technologies LLC  
Nanovector srl  
Novartis AG  
Ocugen Inc  
OliX Pharmaceuticals Inc  
ONL Therapeutics Inc  
OptiKira LLC  
Oxford BioMedica Plc  
Phylogica Ltd  
Precision Biosciences Inc  
Profarma  
ProQR Therapeutics NV  
Recursion Pharmaceuticals Inc  
ReNeuron Group Plc  
Retinagenix LLC  
SanBio Inc  
SparingVision SAS  
Staidson BioPharma Inc  
Sumitomo Dainippon Pharma Co Ltd  
Wave Life Sciences Ltd  
Retinitis Pigmentosa (Retinitis) - Drug Profiles  
Retinitis Pigmentosa (Retinitis) - Dormant Projects  
Retinitis Pigmentosa (Retinitis) - Discontinued Products  
Retinitis Pigmentosa (Retinitis) - Product Development Milestones  
Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2019  
Number of Products under Development by Companies, H2 2019  
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019  
Number of Products under Development by Universities/Institutes, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Products under Development by Companies, H2 2019 (Contd..2), H2 2019  
Products under Development by Companies, H2 2019 (Contd..3), H2 2019  
Products under Development by Companies, H2 2019 (Contd..4), H2 2019  
Products under Development by Universities/Institutes, H2 2019  
Number of Products by Stage and Target, H2 2019  
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019  
Number of Products by Stage and Mechanism of Action, H2 2019  
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Retinitis Pigmentosa (Retinitis) - Pipeline by 4D Molecular Therapeutics Inc, H2 2019  
Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc, H2 2019  
Retinitis Pigmentosa (Retinitis) - Pipeline by Advanced Medical Projects, H2 2019  
Retinitis Pigmentosa (Retinitis) - Pipeline by Allegro Ophthalmics LLC, H2 2019  
Retinitis Pigmentosa (Retinitis) - Pipeline by Allergan Plc, H2 2019  
Retinitis Pigmentosa (Retinitis) - Dormant Projects, H2 2019  
Retinitis Pigmentosa (Retinitis) - Dormant Projects, H2 2019 (Contd..1), H2 2019  
Retinitis Pigmentosa (Retinitis) - Discontinued Products, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019



## I would like to order

Product name: Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/R61ADF79FA1EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R61ADF79FA1EN.html>